Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Medtronic Plc (2M6.DE)
EUR69.52
-3.78 (-5.16%)
IE XETRA Healthcare Medical - Specialties
Address
Building Two 48619
Galway, NW, IE
Galway, NW, IE
CEO
Geoffrey Straub Martha
Website
medtronic.com
IPO
2007-12-28
ISIN IE00BTN1Y115
Also trades on
Deutsche Börse · 2M6.DE (EUR)
London Stock Exchange · 0Y6X.L (USD)
New York Stock Exchange · MDT (USD)
Description
Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
EUR69.52
-3.78 (-5.16%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2.0K
Beta
0.60
Float Shares
1.28B
Free Float %
99.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +5.66% | +7.64% | +3.57% | -15.07% | -19.99% | -13.93% | -6.43% | -10.14% | -31.36% | -3.90% | +67.10% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (49 ratings, all time)
Buy
Price Targets & DCF
Current price
69.52
DCF (Unlevered)
90.77
+30.6%
DCF (Levered)
75.03
+7.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Quality scores
Altman Z-Score
2.77
Grey zone
Piotroski F-Score
6 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Specialties: +8.3%+8.4% ★ Q2'26: +9.8% (vs Q2'25)
-
EPS growth Medical - Specialties: +10.1%+3.3% Q2'26: +17.1% (vs Q2'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%+14.1% Q2'26: +21.3% (vs Q2'25)
-
EBIT margin Medical - Specialties: +12.6%+20.7% ★ Q2'26: +23.2% (vs Q2'25)
-
ROIC Medical - Specialties: +6.6%— Q2'26: +9.1% (vs Q2'25)
-
Share dilution Medical - Specialties: 0.0%-0.1% ★ Q2'26: +0.0% (vs Q2'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×— Q2'26: 3.09× (vs Q2'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Apr 1996 actual |
Apr 1997 actual |
Apr 1998 actual |
Apr 1999 actual |
Apr 2000 actual |
Apr 2001 actual |
Apr 2002 actual |
Apr 2003 actual |
Apr 2004 actual |
Apr 2005 actual |
Apr 2006 actual |
Apr 2007 actual |
Apr 2008 actual |
Apr 2009 actual |
Apr 2010 actual |
Apr 2011 actual |
Apr 2012 actual |
Apr 2013 actual |
Apr 2014 actual |
Apr 2015 actual |
Apr 2016 actual |
Apr 2017 actual |
Apr 2018 actual |
Apr 2019 actual |
Apr 2020 actual |
Apr 2021 actual |
Apr 2022 actual |
Apr 2023 actual |
Apr 2024 actual |
Apr 2025 actual |
Apr 2026 19 Rev. Ana. 7 EPS Ana. |
Apr 2027 21 Rev. Ana. 11 EPS Ana. |
Apr 2028 24 Rev. Ana. 7 EPS Ana. |
Apr 2029 14 Rev. Ana. 6 EPS Ana. |
Apr 2030 12 Rev. Ana. 9 EPS Ana. |
Apr 2031 21 Rev. Ana. 7 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.17B
est: 2.21B (-2.0%)
|
2.44B
est: 2.44B (-0.1%)
|
2.60B
est: 2.66B (-2.0%)
|
4.13B
est: 4.19B (-1.2%)
|
5.01B
est: 4.97B (+0.9%)
|
5.55B
est: 5.67B (-2.1%)
|
6.41B
est: 6.50B (-1.3%)
|
7.67B
est: 7.74B (-1.0%)
|
9.09B
est: 9.02B (+0.8%)
|
10.05B
est: 10.26B (-2.0%)
|
11.29B
est: 11.46B (-1.5%)
|
12.30B
est: 12.45B (-1.2%)
|
13.52B
est: 13.57B (-0.4%)
|
14.60B
est: 14.83B (-1.5%)
|
15.82B
est: 16.04B (-1.4%)
|
15.93B
est: 16.16B (-1.4%)
|
16.18B
est: 16.54B (-2.2%)
|
16.59B
est: 16.76B (-1.0%)
|
17.01B
est: 17.27B (-1.5%)
|
20.26B
est: 25.20B (-19.6%)
|
28.83B
est: 25.08B (+15.0%)
|
29.71B
est: 27.25B (+9.0%)
|
29.95B
est: 24.58B (+21.9%)
|
30.56B
est: 27.23B (+12.2%)
|
28.91B
est: 27.10B (+6.7%)
|
30.12B
est: 24.97B (+20.6%)
|
31.69B
est: 30.38B (+4.3%)
|
31.23B
est: 28.09B (+11.2%)
|
32.36B
est: 37.32B (-13.3%)
|
33.54B
est: 33.53B (+0.0%)
|
36.14B
35.81B – 36.28B
+7.8% YoY
|
39.05B
38.41B – 41.21B
+8.0% YoY
|
40.23B
36.97B – 41.86B
+3.0% YoY
|
42.01B
39.95B – 44.02B
+4.4% YoY
|
44.28B
42.10B – 46.39B
+5.4% YoY
|
45.82B
43.57B – 48.01B
+3.5% YoY
|
| EBITDA |
748.00M
est: 590.20M (+26.7%)
|
1.05B
est: 884.07M (+18.2%)
|
1.26B
est: 1.08B (+16.6%)
|
1.58B
est: 1.35B (+17.4%)
|
1.93B
est: 1.26B (+53.5%)
|
2.18B
est: 2.16B (+0.5%)
|
2.48B
est: 2.21B (+12.3%)
|
3.06B
est: 2.20B (+39.1%)
|
3.62B
est: 3.19B (+13.5%)
|
3.91B
est: 3.69B (+5.9%)
|
4.25B
est: 3.41B (+24.6%)
|
4.32B
est: 4.12B (+4.9%)
|
3.78B
est: 4.62B (-18.2%)
|
5.07B
est: 3.97B (+27.7%)
|
5.12B
est: 3.53B (+44.9%)
|
4.92B
est: 4.53B (+8.6%)
|
5.33B
est: 4.35B (+22.5%)
|
5.46B
est: 5.10B (+7.0%)
|
4.93B
est: 5.06B (-2.5%)
|
5.46B
est: 7.39B (-26.1%)
|
8.54B
est: 4.37B (+95.5%)
|
8.61B
est: 6.33B (+36.1%)
|
9.47B
est: 6.73B (+40.7%)
|
9.30B
est: 5.31B (+75.2%)
|
7.81B
est: 6.80B (+14.9%)
|
7.52B
est: 6.42B (+17.1%)
|
8.78B
est: 7.12B (+23.4%)
|
8.70B
est: 7.57B (+14.8%)
|
8.20B
est: 8.09B (+1.4%)
|
9.22B
est: 9.66B (-4.6%)
|
10.40B
10.31B – 10.44B
+7.7% YoY
|
11.24B
11.05B – 11.86B
+8.0% YoY
|
11.58B
10.64B – 12.05B
+3.0% YoY
|
12.09B
11.50B – 12.67B
+4.4% YoY
|
12.74B
12.12B – 13.35B
+5.4% YoY
|
13.19B
12.54B – 13.82B
+3.5% YoY
|
| EBIT |
636.00M
est: 400.51M (+58.8%)
|
913.80M
est: 713.39M (+28.1%)
|
1.09B
est: 889.70M (+22.7%)
|
1.36B
est: 1.08B (+25.7%)
|
1.68B
est: 950.18M (+77.2%)
|
1.88B
est: 1.85B (+1.6%)
|
2.15B
est: 1.69B (+26.8%)
|
2.65B
est: 1.83B (+45.4%)
|
3.18B
est: 2.74B (+16.3%)
|
3.44B
est: 3.18B (+8.3%)
|
3.71B
est: 2.79B (+32.7%)
|
3.74B
est: 3.34B (+12.0%)
|
3.14B
est: 3.65B (-14.0%)
|
2.81B
est: 3.03B (-7.3%)
|
4.35B
est: 2.84B (+53.2%)
|
4.11B
est: 4.25B (-3.1%)
|
4.49B
est: 4.09B (+9.8%)
|
4.64B
est: 4.35B (+6.6%)
|
4.08B
est: 4.53B (-9.8%)
|
4.15B
est: 6.33B (-34.4%)
|
5.72B
est: 4.04B (+41.7%)
|
5.70B
est: 5.53B (+2.9%)
|
6.82B
est: 5.33B (+28.0%)
|
6.64B
est: 6.86B (-3.2%)
|
5.15B
est: 5.50B (-6.4%)
|
4.82B
est: 4.41B (+9.4%)
|
6.07B
est: 4.88B (+24.4%)
|
6.00B
est: 5.19B (+15.6%)
|
5.56B
est: 5.54B (+0.2%)
|
6.36B
est: 7.00B (-9.2%)
|
7.53B
7.47B – 7.56B
+7.7% YoY
|
8.14B
8.01B – 8.59B
+8.0% YoY
|
8.39B
7.71B – 8.73B
+3.0% YoY
|
8.76B
8.33B – 9.18B
+4.4% YoY
|
9.23B
8.78B – 9.67B
+5.4% YoY
|
9.55B
9.08B – 10.01B
+3.5% YoY
|
| Net Income |
437.80M
est: 781.34M (-44.0%)
|
530.00M
est: 482.94M (+9.7%)
|
457.40M
est: 601.46M (-24.0%)
|
468.40M
est: 719.65M (-34.9%)
|
1.10B
est: 555.86M (+97.6%)
|
1.05B
est: 1.26B (-16.9%)
|
984.00M
est: 1.20B (-18.1%)
|
1.60B
est: 1.17B (+36.4%)
|
1.96B
est: 1.86B (+5.2%)
|
1.80B
est: 2.23B (-19.1%)
|
2.55B
est: 2.02B (+26.3%)
|
2.80B
est: 2.77B (+1.3%)
|
2.23B
est: 3.04B (-26.7%)
|
2.17B
est: 2.44B (-11.0%)
|
3.10B
est: 2.35B (+32.1%)
|
3.10B
est: 3.12B (-0.9%)
|
3.62B
est: 3.17B (+14.2%)
|
3.47B
est: 3.67B (-5.4%)
|
3.07B
est: 3.57B (-14.1%)
|
2.68B
est: 5.09B (-47.4%)
|
3.54B
est: 2.72B (+30.2%)
|
4.03B
est: 3.65B (+10.3%)
|
3.10B
est: 3.99B (-22.2%)
|
4.63B
est: 3.23B (+43.5%)
|
4.79B
est: 4.40B (+8.8%)
|
3.61B
est: 4.82B (-25.2%)
|
5.04B
est: 5.34B (-5.6%)
|
3.76B
est: 5.68B (-33.8%)
|
3.68B
est: 6.07B (-39.4%)
|
4.66B
est: 6.72B (-30.7%)
|
7.12B
6.66B – 7.56B
+5.8% YoY
|
7.84B
7.34B – 8.33B
+10.2% YoY
|
8.38B
7.84B – 8.90B
+6.9% YoY
|
9.17B
8.59B – 9.74B
+9.5% YoY
|
10.00B
9.36B – 10.62B
+9.1% YoY
|
10.50B
9.82B – 11.15B
+4.9% YoY
|
| SGA |
695.60M
est: 730.46M (-4.8%)
|
763.30M
est: 767.41M (-0.5%)
|
757.60M
est: 865.87M (-12.5%)
|
1.28B
est: 1.19B (+7.2%)
|
1.59B
est: 1.52B (+4.4%)
|
1.69B
est: 1.82B (-7.4%)
|
1.96B
est: 1.94B (+1.4%)
|
2.37B
est: 2.34B (+1.4%)
|
2.80B
est: 2.76B (+1.4%)
|
3.21B
est: 3.19B (+0.8%)
|
3.66B
est: 3.59B (+1.9%)
|
4.15B
est: 3.97B (+4.5%)
|
4.71B
est: 4.51B (+4.4%)
|
5.15B
est: 5.14B (+0.2%)
|
5.79B
est: 5.57B (+3.9%)
|
5.53B
est: 5.46B (+1.4%)
|
6.07B
est: 5.66B (+7.3%)
|
5.70B
est: 5.70B (0.0%)
|
5.85B
est: 5.86B (-0.3%)
|
6.90B
est: 9.71B (-28.9%)
|
9.47B
est: 7.01B (+35.1%)
|
9.71B
est: 9.77B (-0.7%)
|
9.97B
est: 9.92B (+0.5%)
|
10.42B
est: 10.35B (+0.7%)
|
10.11B
est: 9.73B (+3.9%)
|
10.15B
est: 9.94B (+2.1%)
|
10.29B
est: 11.00B (-6.5%)
|
10.42B
est: 11.71B (-11.1%)
|
10.74B
est: 12.51B (-14.2%)
|
10.85B
est: 11.08B (-2.1%)
|
11.93B
11.82B – 11.98B
+7.7% YoY
|
12.89B
12.68B – 13.60B
+8.0% YoY
|
13.28B
12.20B – 13.82B
+3.0% YoY
|
13.87B
13.19B – 14.53B
+4.4% YoY
|
14.62B
13.90B – 15.31B
+5.4% YoY
|
15.13B
14.38B – 15.85B
+3.5% YoY
|
| EPS |
0.45
est: 0.61 (-25.7%)
|
0.51
est: 0.63 (-19.1%)
|
0.52
est: 0.69 (-25.1%)
|
0.40
est: 0.80 (-49.9%)
|
0.91
est: 0.87 (+4.1%)
|
0.87
est: 0.91 (-4.6%)
|
0.81
est: 1.20 (-32.7%)
|
1.31
est: 1.63 (-19.6%)
|
1.61
est: 1.99 (-19.3%)
|
1.49
est: 2.26 (-34.0%)
|
2.11
est: 2.83 (-25.5%)
|
2.44
est: 3.22 (-24.3%)
|
1.97
est: 4.06 (-51.5%)
|
1.85
est: 4.14 (-55.3%)
|
2.80
est: 4.03 (-30.6%)
|
2.87
est: 4.96 (-42.2%)
|
3.43
est: 4.35 (-21.2%)
|
3.40
est: 4.86 (-30.0%)
|
3.06
est: 5.26 (-41.8%)
|
2.44
est: 4.30 (-43.2%)
|
2.51
est: 4.34 (-42.2%)
|
2.92
est: 4.58 (-36.3%)
|
2.29
est: 4.68 (-51.1%)
|
3.44
est: 5.14 (-33.1%)
|
3.57
est: 4.96 (-28.0%)
|
2.68
est: 4.37 (-38.6%)
|
3.75
est: 5.66 (-33.7%)
|
2.83
est: 5.28 (-46.4%)
|
2.77
est: 8.76 (-68.4%)
|
3.63
est: 5.46 (-33.5%)
|
5.52
5.16 – 5.86
+1.1% YoY
|
6.08
5.69 – 6.46
+10.2% YoY
|
6.50
6.08 – 6.90
+6.9% YoY
|
7.11
6.66 – 7.55
+9.5% YoY
|
7.76
7.26 – 8.24
+9.1% YoY
|
8.14
7.62 – 8.64
+4.9% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-22 | UBS | Neutral | Neutral | Maintain |
| 2026-04-15 | Truist Securities | Hold | Hold | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-25 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-15 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-14 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-05 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-04 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-30 | B | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-29 | B | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-28 | B | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-15 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
7.40B
OE per share TTM
5.75
Owner's Yield
8.84%
Maintenance CapEx ratio
27.17%
Maint CapEx / Avg PPE
18.2%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
79.2K
Shares Outstanding
1.28B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Geoffrey Straub Martha | Chairman of the Board & Chief Executive Officer | 3M | male |
| Brett A. Wall | Executive Vice President & President of Neuroscience Portfolio | 2M | male |
| Michelle Quinn | Executive Vice President, General Counsel & Secretary | 940.1K | female |
| Thierry Pieton | Executive Vice President & Chief Financial Officer | 363.1K | male |
| Alex Gu | Senior VP & President of Greater China Region | — | male |
| Mark Ploof | Senior Vice President of Global Operations and Business Services | — | male |
| Matthew Walter | Senior Vice President of Human Resources, IT and Global Communications & Corporate Marketing | — | male |
| Rogerio Branco | SVP & Chief Operations and Supply Chain Officer | — | male |
| Laura Mauri | Senior Vice President and Chief Scientific & Medical Officer | — | — |
| Denise L. Blomquist | Vice President, Global Controller & Chief Accounting Officer | — | female |
| Ingrid Goldberg | Vice President & Head of Investor Relations | — | female |
| Jason Weidman | Senior VP and President of Coronary & Renal Denervation business | — | male |
ESG Rating
ESG Score History
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2M6.DE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
